FDA approves Noctivia for adults who deal with nocturnal polyuria

The U.S. Food and Drug Administration has approved Noctivia nasal spray for adults who deal with nocturnal polyuria, a condition that causes overproduction of urine during the night.
Nocturia, which is when people awaken at night to urinate, can be caused by numerous conditions, including congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate. Noctivia treats a certain type of nocturia, so individuals must work with health care providers to determine if they suffer from nocturnal polyuria.
“Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,” Dr. Hylton V. Joffe, director of the Division of Bone, Reproductive and Urologic Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “It is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.”